Joseph Manni Sells 1,378 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CRO Joseph Manni sold 1,378 shares of CeriBell stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $18.00, for a total transaction of $24,804.00. Following the completion of the transaction, the executive directly owned 56,291 shares of the company’s stock, valued at $1,013,238. The trade was a 2.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CeriBell Stock Down 0.5%

CBLL opened at $18.70 on Thursday. The stock has a market capitalization of $709.48 million, a price-to-earnings ratio of -11.47 and a beta of 0.99. The company has a fifty day moving average of $19.08 and a two-hundred day moving average of $19.29. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. CeriBell, Inc. has a fifty-two week low of $10.85 and a fifty-two week high of $24.33.

CeriBell (NASDAQ:CBLL) last released its earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). The company had revenue of $26.49 million for the quarter, compared to analysts’ expectations of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. On average, research analysts expect that CeriBell, Inc. will post -1.69 earnings per share for the current year.

Wall Street Analyst Weigh In

CBLL has been the subject of a number of research reports. Canaccord Genuity Group cut their target price on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings cut shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 12th. Finally, BTIG Research reissued a “buy” rating and set a $30.00 target price on shares of CeriBell in a research note on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, CeriBell currently has a consensus rating of “Moderate Buy” and an average target price of $22.20.

Hedge Funds Weigh In On CeriBell

A number of institutional investors and hedge funds have recently bought and sold shares of CBLL. Strs Ohio acquired a new position in CeriBell during the first quarter worth about $27,000. Caitong International Asset Management Co. Ltd boosted its position in CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after acquiring an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell during the third quarter worth about $33,000. CWM LLC boosted its position in CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after acquiring an additional 1,697 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after acquiring an additional 1,801 shares during the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.